Your browser doesn't support javascript.
loading
Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer-Results from the OncoWatch 1.0 Study.
Holländer-Mieritz, Cecilie; Steen-Olsen, Emma Balch; Kristensen, Claus Andrup; Johansen, Christoffer; Vogelius, Ivan Richter; Pappot, Helle.
Afiliação
  • Holländer-Mieritz C; Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
  • Steen-Olsen EB; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Kristensen CA; Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
  • Johansen C; Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
  • Vogelius IR; Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
  • Pappot H; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Cancers (Basel) ; 15(2)2023 Jan 09.
Article em En | MEDLINE | ID: mdl-36672370
ABSTRACT

Background:

Consumer wearables allow objective health data monitoring, e.g., of physical activity and heart rate, which might change over a cancer treatment course. Patients with head and neck cancer (HNC) receiving radiotherapy (RT) with curative intent typically experience side effects such as pain, decreased appetite, and dehydration, which may lead to hospitalizations. Therefore, health data monitoring could be important to understand a patient's condition outside the hospital. The OncoWatch 1.0 study investigated the feasibility of using smartwatches for patients with HNC receiving RT.

Methods:

This study was a prospective, single-cohort feasibility study. The inclusion criteria were patients ≥ 18 years of age who planned to receive curatively intended radiotherapy for HNC. Consenting patients were asked to wear a smartwatch during RT and until two weeks after the end of RT. The primary endpoint was adherence. The secondary endpoints were data acquisition and variations in heart rate and physical activity.

Results:

Ten patients were included, with a median age of 62 years and eight males. The adherence rate for wearing the watch >12 h/d over the study period was 31%. The data acquisition rate was 61%.

Conclusions:

Although the primary endpoint was not reached, new knowledge has been established, including the secure data setup and key points that need to be addressed in future studies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article